Second- and third-generation ALK inhibitors for non-small cell lung cancer

被引：0
作者：
Jingjing Wu
John Savooji
Delong Liu
机构：
[1] The First Affiliated Hospital of Zhengzhou University,Department of Oncology
[2] Westchester Medical Center and New York Medical College,Department of Medicine
来源：
Journal of Hematology & Oncology | / 9卷
关键词：
Brain Metastasis; Pemetrexed; Anaplastic Lymphoma Kinase; Anaplastic Large Cell Lymphoma; Crizotinib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Crizotinib as the first-generation ALK inhibitor has shown significant activity in ALK-mutated non-small cell lung cancer (NSCLC). Second- and third-generation ALK inhibitors are entering clinical applications for ALK+ NSCLC. In addition, a third-generation ALK inhibitor, lorlatinib (PF-06463922), was reported to resensitize NSCLC to crizotinib. This review provided a summary of clinical development of alectinib, ceritinib, brigatinib (AP26113), and lorlatinib.
引用
收藏
相关论文
共 50 条
  • [21] Future options for ALK-positive non-small cell lung cancer
    Iacono, Daniela
    Chiari, Rita
    Metro, Giulio
    Bennati, Chiara
    Bellezza, Guido
    Cenci, Matteo
    Ricciuti, Biagio
    Sidoni, Angelo
    Baglivo, Sara
    Minotti, Vincenzo
    Crino, Lucio
    LUNG CANCER, 2015, 87 (03) : 211 - 219
  • [22] Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancer
    Mattsson, Johanna S. M.
    Brunnstrom, Hans
    Jabs, Verena
    Edlund, Karolina
    Jirstrom, Karin
    Mindus, Stephanie
    la Fleur, Linnea
    Ponten, Fredrik
    Karlsson, Mats G.
    Karlsson, Christina
    Koyi, Hirsh
    Branden, Eva
    Botling, Johan
    Helenius, Gisela
    Micke, Patrick
    Svensson, Maria A.
    BMC CANCER, 2016, 16
  • [23] The efficacy and safety of ALK inhibitors in the treatment of ALK-positive non-small cell lung cancer: A network meta-analysis
    Fan, Junsheng
    Fong, Tszhei
    Xia, Zengfei
    Zhang, Jian
    Luo, Peng
    CANCER MEDICINE, 2018, 7 (10): : 4993 - 5005
  • [24] Advancements of ALK inhibition of non-small cell lung cancer: a literature review
    Zia, Victor
    Lengyel, Csongor Gyorgy
    Tajima, Carla Chizuru
    de Mello, Ramon Andrade
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (07) : 1563 - 1574
  • [25] First- versus Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases
    Tatineni, Vineeth
    O'Shea, Patrick J.
    Ozair, Ahmad
    Khosla, Atulya A.
    Saxena, Shreya
    Rauf, Yasmeen
    Jia, Xuefei
    Murphy, Erin S.
    Chao, Samuel T.
    Suh, John H.
    Peereboom, David M.
    Ahluwalia, Manmeet S.
    CANCERS, 2023, 15 (08)
  • [26] Economic burden in patients with ALK plus non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors
    Lin, Huamao M.
    Pan, Xiaoyun
    Hou, Peijie
    Huang, Hui
    Wu, Yanyu
    Ren, Kaili
    Jahanzeb, Mohammad
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (08) : 894 - 901
  • [27] Clinical data and role of ceritinib a second-generation ALK tyrosine kinase inhibitor for the treatment of ALK positive non-small cell lung cancer
    Rothschild, Sacha I.
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S1173 - S1176
  • [28] ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer
    Mota, Ines
    Patrucco, Enrico
    Mastini, Cristina
    Mahadevan, Navin R.
    Thai, Tran C.
    Bergaggio, Elisa
    Cheong, Taek-Chin
    Leonardi, Giulia
    Karaca-Atabay, Elif
    Campisi, Marco
    Poggio, Teresa
    Menotti, Matteo
    Ambrogio, Chiara
    Longo, Dario L.
    Klaeger, Susan
    Keshishian, Hasmik
    Sztupinszki, Zsofia M.
    Szallasi, Zoltan
    Keskin, Derin B.
    Duke-Cohan, Jonathan S.
    Reinhold, Bruce
    Carr, Steven A.
    Wu, Catherine J.
    Moynihan, Kelly D.
    Irvine, Darrell J.
    Barbie, David A.
    Reinherz, Ellis L.
    Voena, Claudia
    Awad, Mark M.
    Blasco, Rafael B.
    Chiarle, Roberto
    NATURE CANCER, 2023, 4 (07) : 1016 - +
  • [29] TRK Inhibitors in Non-Small Cell Lung Cancer
    Harada, Guilherme
    Lara Gongora, Aline Bobato
    da Costa, Cesar Martins
    Santini, Fernando Costa
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2020, 21 (05)
  • [30] Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors
    Sgambato, Assunta
    Casaluce, Francesca
    Maione, Paolo
    Gridelli, Cesare
    EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (01) : 71 - 80
12345